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High-altitude pulmonaryedema (HAPE) isa life-threatening diseaseofhigh altitude thatoften aﬀects nonacclimatizedapparently
healthy individuals who rapidly ascend to high altitude. Early detection, early diagnosis, and early treatment are essential to
maintainthesafetyofpeople whoascendtohighaltitude, suchasconstructionworkersandtourists.Inthispaper,Idiscussvarious
methods and criteria that can be used for the early diagnosis and prediction of HAPE. I also discuss the preventive strategies and
options for on-site treatment. My objective is to improve the understanding of HAPE and to highlight the need for prevention,
early diagnosis, and early treatment of HAPE to improve the safety of individuals ascending to high altitude.
1.Introduction
High-altitude pulmonary edema (HAPE) is a speciﬁc disease
of high altitude. It has a high incidence and is often serious
because of its rapid progresses. It is also life-threatening if
treatment is not started in a timely manner [1, 2].
Many studies [3, 4] have shown that HAPE is a major
disease thatoften aﬀectsnonacclimatized healthy individuals
who ascend to high altitudes. Therefore, early diagnosis
of HAPE is essential to initiate early treatment of HAPE
and maintain the safety of people who ascent to high
altitude. Although international and Chinese criteria have
been established for HAPE [5], its early detection and
diagnosis are diﬃcult, except in the presence of typical
pulmonary edema. Following the magnitude 7.1 earthquake
that struck Yushu (Yushu Tibetan Autonomous Prefecture,
Qinghai Province, China) on April 14, 2010, approximately
50,000 rescuers assembled in the region. This region lies
at an altitude ranging from 3700m to 4900m, the average
altitude is 4,493m. Although the incidence of HAPE is only
2–4%, the sudden inﬂux of nonacclimatized rescuers to the
region meant that HAPE was one of the most common
life-threatening diseases at that time, even considering the
eﬀectsoftheearthquake,which caused1944deaths,with 216
people missing and 12,135 injured.
HAPEcan also induce psychological disorders in aﬀected
individuals. Therefore, it is essential to highlight the early
diagnosis and on-site treatment ofHAPE.Underthe support
of the National Science and Technology Program, we have
conducted an extensive range of studies on HAPE intended
to ﬁnd eﬀective methods for early diagnosis and clinical
treatment of HAPE and, thus, improve the health and safety
of individuals who rapidly ascend to high altitude.
2.MethodsfortheEarlyDiagnosis ofHAPE
It is generally not diﬃcult for physicians to diagnose typical
HAPE, which is based on medical history, symptoms, and
signs including white, yellow, or pink frothy sputum, moist
rales on pulmonary auscultation, and ﬂocculent shadows
on chest X-rays. However, atypical HAPE is much more
diﬃcult to diagnose. Patients usually develop atypical HAPE
at altitude <3000m, which may occur several days or longer
after ascending to altitude. Symptoms diﬀer from those
of typical HAPE, such as less sputum or an absence of
sputum and nonspeciﬁc ﬁndings on chest X-rays. Based
on a previous study [6], the development of HAPE can be
classiﬁed into two stages from the onset to the presence
of typical symptoms. The early stage is characterized by2 Pulmonary Medicine
interstitialpulmonaryedemawhilethelatestageischaracter-
ized by alveolar pulmonary edema. Patients with interstitial
pulmonary edema do not usually exhibit serious dyspnea
or typical signs such as pink frothy sputum, extensive
moist rales, or wheezy phlegm. Thus, these patients are
susceptible to misdiagnosis and delayed treatment. Li et al.
[7] investigated the characteristics of HAPE in 482 patients.
They examined the clinical symptoms and signs, and
performed routine blood tests, electrocardiography, color
Doppler echocardiography, chest X-rays, and computed
tomography (CT) of the patients. They found that HAPE
patients exhibited signiﬁcant diﬀerences in these parameters
compared with non-HAPE patients, and that the symptoms
and signs were more obvious in HAPE patients than in
non-HAPE patients. In addition, studies have revealed that
oxygen treatment is more eﬀective in HAPE than in other
forms of lung injury. Therefore, some researchers have
proposed that tentative oxygen treatment can be used for the
early diagnosis of HAPE. Nevertheless, the most important
examinations for the early diagnosis of HAPE are chest
X-rays or CT. On chest X-rays, HAPE often presents as
decreased pulmonary transmittance, increased or obscure
lung markings, and ground glass-like changes in the lung,
or patchy shadows. On CT scans, increased and enlarged
lung markings, ground glass-like changes in the lung,
nodule-like shadows, scattered or isolated alveolar edema
of terminal bronchioles, and slim reticulate shadows can be
observed.
3.Diagnosisand Gradingof HAPE
3.1. Criteria for Early Diagnosis of HAPE. According to the
clinical symptoms, signs, and ﬁndings of blood routine tests,
electrocardiography, color Doppler echocardiography, chest
X-rays, and CT, the following criteria for HAPE have been
developed [7]:
(1) recentascenttohighaltitude(>3000m);thepresence
of palpitations, chest tightness, dyspnea and cough
with or without white foamy sputum;
(2) local, unilateral, or bilateral coarse breath sounds,
with or without local moist rales, central cyanosis,
tachycardia (>100/min), and tachypnea (>24/min);
(3) chest X-ray ﬁndings including decreased pulmonary
transmittance, increased or obscure lung markings,
ground glass-like changes or patchy shadows in the
lung; CT ﬁndings including increased and enlarged
lung markings, ground glass-like changes, nodule-
like shadows, scattered or isolated alveolar edema of
terminal bronchioles and slim reticulate shadows;
(4) routinebloodtestﬁndingsincludeanincreased white
blood cell count and an increased neutrophil count;
(5) arterial blood gas analysis showing continuous
hypoxemia accompanied by mild respiratory alkalo-
sis;
(6) electrocardiographic ﬁndings including sinus tachy-
cardia, clockwise rotation and sharp P waves;
(7) persistent pulmonary hypertension on echocardiog-
raphy;
(8) symptoms resolve rapidly following rest, oxygen
treatment, pulmonary artery pressure lowering treat-
ment, and diuresis.
For the diagnosis of HAPE, criteria 1, 2 and 3 must be
met. These ﬁndings, together with those in 4, 5, 6, 7, and/or
8, are then used to conﬁrm HAPE. Using these criteria,
the severity of disease can be determined, which is critical
for individualized therapy. With early diagnosis and early
treatment, HAPE can be controlled at the early stage and the
symptoms be markedly improved.
3.2. Criteria for the Grading of HAPE. Once HAPE is diag-
nosed,itsseverityshouldbegradedtoprovideindividualized
therapy. Therefore, when a patient with suspected HAPE is
admitted, the grade of HAPEshould be conﬁrmed as soon as
possible according to the criteria for early diagnosis [8].
3.2.1. Mild. Dyspnea and cough with white foamy sputum
may occur after intermediate manual labor. Lung auscul-
tation shows local moist rales in a unilateral lung. The
respiratory rate is often <24breaths/min, and heart rate
<100beats/min. There is no arrhythmia. Chest X-rays shows
the area of ﬂocculent shadows occupies <1/4 of the lung.
The shadows are conﬁned to the right lower lobe and are
spottyorpatchy.CT scansrevealincreased and enlargedlung
markings. Routine blood tests are normal.
3.2.2. Moderate. Dyspnea, chest pain, chest tightness, and
cough with a large amount of white foamy sputum occur
after mild manual labor. Extensive moist rales are noted
in the bilateral lower lung or unilateral lung on lung
auscultation. The respiratory rate is >24breaths/min while
the heart rate is >110beats/min and is accompanied by
arrhythmia. Chest X-rays show patchy or ﬂocculent shadows
covering >1/2 of the lung, and CT scans show ground glass-
like changes or nodule-like shadows. The white blood cell
count and neutrophil count are slightly increased.
3.2.3. Severe. Patients can not lie in the supine or prone
position. They may have a pale complexion, cold sweat on
the forehead, serious dyspnea, and a heavy cough with a
large amount of white or pink foamy sputum. Rales of small,
intermediate, and large bubbles are extensive in the bilateral
lungs and are accompanied by the sound of boiling water.
The respiratory rate is >30breaths/min, while the heart rate
is >120beats/min and is accompanied by arrhythmia. Chest
X-rays reveal asymmetric cloudy shadows covering >1/2 of
thebilaterallungs,andCTscansindicatescatteredorisolated
alveolar edema of the terminal bronchioles. The white blood
cell count is 10 ×109/L.
3.2.4. Extremely Severe. T h es y m p t o m sa n ds i g n sa r em o r e
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of dying. They have a pale complexion, weak breathing, and
a large amount of foam is discharged from the nose and
mouth.Agurglingsoundisaudibleinthebilaterallungs.The
heart sounds are weak, and blood pressure is decreased. The
patient is also likely to have high-altitude cerebral edema.
Heart failure and secondary pulmonary infection are very
likely. Chest X-rays reveal ﬂocculent shadows in unilateral or
bilateral lungs, enlargement of the heart, and the pulmonary
artery is particularly clear. CT scans show diﬀuse alveolar
edema in unilateral or bilateral lungs. The number of white
blood cells is > 16 × 109/L.
4.GuidelinesforOn-Site Treatmentof HAPE
4.1. Guidelines for the Treatment of HAPE. In terms of phar-
macotherapy, there is no consensus on the types of drugs,
their doses, or administration routes for HAPE. Thus, it is
imperative todevelopguidelinesto standardize and optimize
the treatment of HAPE. Based on the experience of several
mountain sickness treatment centers and the eﬃcacy of
currently available drugs and strategies, in combination with
recent advances in the treatment of HAPE, our research
group proposed four regimens for early diagnosis and treat-
ment of HAPE and conducted a prospective, randomized,
controlled study to investigate their eﬃcacy. A total of 400
patients with HAPE were divided into four groups and
treated as follows: patients in group A received oxygen
inhalation, dexamethasone, and aminophylline; patients in
group B-C were treated as in group A, in addition to diuresis
with furosemide in group B, blood pressure-lowering with
nifedipine in group C, or L-arginine in group D. The eﬃcacy
and safety of these therapeutic regimens were compared.
The treatment showing greatest therapeutic eﬃcacy was
subsequentlyusedtopreparetheguidelinesforthetreatment
of HAPE. Overall, all four regimens were eﬀective for the
treatment of HAPE [9]. However, in terms of the time to
resolution of symptom and signs, the time to resolution
of chest X-ray ﬁndings, and duration of hospitalization,
regimen B was superior to the other regimens. Interestingly,
there were no marked diﬀerences between regimens A,
C, and D. Furthermore, there were no diﬀerences in the
incidence of adverse eﬀects between regimens A, B, and
D, or in the liver and kidney functions between all four
regimens. These ﬁndings suggest that a regimen composed
of oxygen inhalation, dexamethasone, aminophylline, and
furosemide is eﬀective, well tolerated, simple to follow, and
thusoﬀers a basic, standardized regimen for the treatment of
HAPE
Once the regimen has been selected, timely initiation
of individualized treatment is a key factor that contributes
towards its therapeutic eﬃcacy. Our experience of on-site
treatment of more than 300 patients with HAPE has shown
that on-site individualized treatment is feasible, without
increasing therisk for death[10]. FollowingtheYushu earth-
quake, the eﬃcacy of this regimen was further conﬁrmed as
the prognosis after on-site treatment was signiﬁcantly better
thanthatafterblindevacuation,whichusuallyresultsinpoor
outcomes.
4.2. Principles of Individualized Treatment of HAPE. The
principles of individualized treatment of HAPE are highly
dependent on the severity of HAPE [11].
4.2.1. Mild. Bed rest, intermittent oxygen inhalation or sub-
cutaneous oxygen treatment, oral aminophylline (250mg),
prednisone (10mg), furosemide (20mg), atropine or aniso-
damine (5mg) twice daily, and other treatments for speciﬁc
symptoms are recommended.
4.2.2. Moderate. Absolute bed rest, continuous oxygen in-
halation or subcutaneous oxygen treatment are necessary.
Drugs are mainly administered intramuscularly, accompa-
nied by oral and intravenous medication. Aminophylline
(250mg), prednisone (10mg), furosemide (20mg), atropine
or anisodamine (5mg) three to four times daily, and other
treatments for speciﬁc symptoms are recommended.
4.2.3. Severe. Absolute bed rest, preferably in a semirecum-
bent position and continuous high-ﬂow oxygen inhalation
with defoaming agents in a humidiﬁer bottle are nec-
essary. Drugs are mainly administered intravenously and
intramuscularly. Atropine (2–5mg/0.5h) or anisodamine
(20–40mg/0.5h), dexamethasone (10mg/4h), furosemide
(40mg/8h), gentamicin (80000IU/8h); or dexamethasone
(200mg), furosemide (40mg), atropine or anisodamine
(10mg), and gentamicin (160000IU) in 10% glucose solu-
tion (500mL) three times daily are recommended. Symp-
tomatic treatments may include intramuscular morphine
(10mg) for patients with dysphoria, intramuscular cedilanid
(0.4–0.8mg) for patients with heart failure, and vitamin C,
ATP solution, coenzyme A, and cytochrome C, as deemed
necessary.
4.2.4. Extremely Severe. On-site treatment is preferred, fol-
lowed by escalation therapy during evacuation once the
patient’s condition has stabilized. The procedures for the
treatment of extremely severe HAPE are similar to those of
severe HAPE, except for the treatment of complications. For
patients with cerebral edema, the doses of dexamethasone
and diuretics should be increased and airway maintenance
is necessary. Hyperbaric oxygen treatment or oxygen inhala-
tionthroughaventilatorisalsorecommended.Hypothermia
is beneﬁcial for the brain. For patients with serious heart
failure, half or two-thirds of the recommended dose of
digitalis should be administered in combination with an
appropriate dose of a sedative. The daily dose of glucose
should be <400g to maintain low energy consumption and
to promote osmotic diuresis. The treatments should be
escalated during evacuation once the patient’s condition has
stabilized.
The following factors are particularly important during
evacuation. (1) Mode of transport: the patient should be
transported in a vehicle that can provide rapid and steady
evacuation. Such transportation options include helicopter,
motor truck, heavy-duty medical car, and miniambulance.
The vehicle’s speed should be carefully controlled, particu-
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in a horizontal position and excess movement is avoided.
(2) Accompanying personnel: the patient should be ideally
accompanied by one nurse and one physician, or at least one
medical staﬀ who can provide eﬀective on-site treatment,
The personnel should continuously monitor and record
the patient’s vital signs and perform treatment as deemed
necessary. (3) Patient position: the patient should be kept
in a semirecumbent position, and airway maintenance is
essential. However, the supine position is recommended for
patients in a coma. Head vibration and bumps should be
avoidedto prevent cerebral hernia. (4) For deceased patients,
the time of death and the patients symptoms and signs at
death should be recorded, and the body should remain in a
stable position.
4.2.5. Symptomatic Treatment. For patients with suspected
heart failure, treatment with digitalis (e.g., cedilanid and
digoxin) is recommended to improve myocardial contrac-
tility. For patients with low blood pressure, dextran and
hydroxyethyl starch 40 is recommended for blood volume
expansion. For patients with secondary infections, penicillin
or other antibiotics can be administered. For patients with
dysphoria, sedatives can be given according to the disease
state.
In summary, patients with mild to moderate HAPE
should receive basic treatment plus any supplementary
treatmentrequired.Patientswithsevereandextremelysevere
HAPE should also receive treatment for any symptoms.
Basic treatment consists of bed rest, oxygen inhalation, and
intravenous administration of aminophylline, dexametha-
sone, and furosemide. Supplementary treatments include
antibiotics, vitamin C, and cytochrome C, for example.
4.3. Pathophysiological Evidence for the On-Site
Treatment of HAPE
4.3.1. Bed Rest. Physical activity may lead to contraction
of pulmonary vessels resulting in an increase in pulmonary
artery pressure and a decrease in arterial partial pressure of
oxygen. Therefore, absolute bed rest can reduce muscular
activity and contraction of blood vessels and, thus, provide
stable pulmonary artery pressure. In some studies [12], bed
rest alone was used for the treatment of mild HAPE.
4.3.2. Oxygen Inhalation. Oxygen inhalation can decrease
the pulmonary artery pressure. Evidence shows that inhala-
tion of 100% oxygen can signiﬁcantly decrease the increased
pulmonary artery pressure andi sa c c o m p a n i e db yi m p r o v e -
ments in symptoms [13]. In addition, oxygen inhalation can
increase arterial oxygen saturation and improve tissue oxy-
gen supply, thus alleviating hypoxia. For patients with severe
HAPE, hyperbaric oxygen is preferred. Some researchers
[14, 15] have proposed mechanical ventilation for patients
with respiratory distress. Hyperbaric oxygen treatment not
only increases the oxygen concentration and subsequently
the alveolar and arterial partial pressure of oxygen, but also
increases pulmonary ventilationandalveolar pressure,which
inhibit ﬂuid exudation. Oxygen inhalation can also rectify
respiratory alkalosis, which prevents the transportation of
peripheral blood to the lung.
4.3.3. Nitric Oxide Inhalation. Experimental studies have
shown that hypoxia results in reduced nitric oxide levels,
a principle cause of pulmonary vasoconstriction and that
inhalation of nitric oxide can reduce hypoxic pulmonary
hypertension, improve the patient’s ventilation to perfusion
ratio, improve hypoxemia, and improve HAPE in patients
with signs and symptoms, as well as decrease hospitalization
time with few adverse eﬀects. Accordingly, we suggest that
nitric oxideinhalation should be considered in the treatment
of HAPE. It should be administered via a nasal catheter at
a dose of 10ppm (0.001%) at a ﬂow rate of 3–5L/min for
30min in normal air or in oxygen.
4.3.4. Aminophylline. Aminophylline is a classic bronchod-
ilator and has long been used in the treatment of HAPE.
Aminophylline can dilate the bronchus, decrease hypoxic
pulmonary hypertension, enhancediaphragmfunction, sup-
press lipid peroxidation and hypoxia-induced pulmonary
vascular inﬂammation, enhance cardiac function and diure-
sis, clear bronchial mucus, and subsequently resolve moist
rales. Unlikeotherbronchodilators, aminophylline can dilate
both the bronchus and vascular smooth muscle; hence, it
is preferred over other bronchodilators for the treatment of
HAPE.
4.3.5. Anticholinergics. Some hospitals use anisodamine
(654-2) instead ofaminophylline for the treatment of HAPE.
Anisodamine can improve pulmonary vascular spasms, de-
crease pulmonary vascular resistance and hypoxic pulmo-
nary hypertension, improve the pulmonary microcircula-
tion, and maintain smooth pulmonary blood ﬂow. As a
result, anisodamine inhibits intravascular coagulation and,
thus, reduces the risk of pulmonary embolism.
4.3.6. Nifedipine. Nifedipine is a calcium channel blocker
that inhibits release of catecholamines from sympathetic
nerve endings. Therefore, it is an eﬀective vasodilator,
reduces hypoxic pulmonary hypertension, increases arterial
oxygen tension, improves the symptoms and signs of HAPE,
lowers right atrial pressure, and increases cardiac output.
Therefore, nifedipine targets many of the eﬀects of HAPE.
4.3.7. Dehydration and Diuresis. Hypoxia can lead to redis-
tribution of systemic blood and abrupt increases in pul-
monary blood volume. Furosemide and chlorothiazide not
only promote diuresis and dehydration, but also increase
renal blood ﬂow and reduce left ventricular ﬁlling pressure.
Thus, blood in the lungs is transported to the periphery,
improving pulmonary congestion. In addition, oral aceta-
zolamide can play a signiﬁcant role in the treatment of
HAPE because it can increase urine output in patients
with HAPE or ﬂuid retention. Acetazolamide is a carbonic
anhydrase inhibitor that inhibits carbonic anhydrase activity
in the brain, kidney, and blood. In the kidney, acetazolamide
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inhibits sodium bicarbonate reabsorption to increase urine
output and, thus, reduce sodium and water retention. In the
brain, acetazolamide inhibits brain choroid plexus carbonic
anhydrase activity to reduce cerebrospinal ﬂuid production
rate and hence reduce intracranial pressure.
4.3.8. Dexamethasone. Dexamethasone is an analog of
adrenocortical hormones that can improve the functions
of capillary endothelial cells and alveolar epithelial cells,
decrease pulmonary capillary permeability, protect alveolar
epithelial type II cells, promote the secretion of pulmonary
surfactant, increase renal blood ﬂow, and decrease the
secretion of antidiuretic hormone. Thus, dexamethasone is
a key drug in the treatment of HAPE.
5.EarlyPredictionofHAPE
HAPE is a disease that is very diﬃcult to predict. Although
much research has been done in attempts to predict HAPE,
no consensus has been reached regarding markers for the
early prediction of HAPE. However, many studies have sug-
gested that HAPE could be predicted based on physiological
functions, molecular biology, or genetic predisposition.
5.1. Physiological Parameters
5.1.1.OxygenSaturation. Respiratorygasexchangedisorders
may predict serious hypoxemia and even acute mountain
sickness in individuals who rapidly ascend to high altitude.
Thus, monitoring arterial oxygen saturation (SaO2)c a nb e
used to predict HAPE. Studies have shown that 80–100% of
patientswithserioushypoxemiadevelopHAPE.Accordingly,
Roach et al. [16] speculated that noninvasive measurement
of SaO2 was a simple and convenient way to predict the
onset of HAPE. Similarly, Burtscher et al. [17] suggested that
measurement of SaO2 could be used to predict the onset
of acute mountain sickness. In a prospective cohort study,
Shen et al. [18] found that there were signiﬁcant individual
diﬀerencesinthechanges inoxygensaturationwithincreases
in altitude. They found that when the SaO2 decreased by
>30% at low altitude, the susceptibility to HAPE increased
markedly and about 62% of the participants developed
HAPE. Thus, they speculated that a decrease in SaO2 > 30%
oﬀers a biomarker to predict susceptibility to HAPE.
5.1.2. Maximal Oxygen Uptake. Zhang et al. [19]u s e ds u b -
maximal bench stepping to directly calculate maximal oxy-
gen uptake (VO2max), which was then applied to predict
HAPE. They conducted this study in soldiers ascending to
high altitude. They found that soldiers with a VO2max ≥
3L/min at sea level were less likely to develop HAPE than
those with a VO2max < 3L/min.
5.1.3. Forced Vital Capacity (FVC). W a n ga n dZ h o u[ 20]
measured FVC, body surface area, and thoracic volume in
an eﬀort to predict HAPE in individuals ascending to high
altitude. They found that a FVC/body surface area <3L/m 3,
FVC/thoracic volume <400L/m3, lung/body index >30, and
lung/thorax index >0.24 were associated with increased risk
for HAPE.
5.1.4. PulmonaryDiﬀusionFunction. Geng et al.[21]in v es ti-
gated the diﬀusion of carbon monoxide (CO) in the lung of
27 subjects who rapidly ascended from 2260m to 4700m.
They found that CO diﬀusion was correlated with the
developmentof acute mountain sickness. In 10 patients with
HAPE, the diﬀusing capacity of CO (DLCO) increased with
increasing altitude, but the amplitude of this increase was
greater in subjects without HAPE. Thus, they speculated
that insuﬃcient DLCO was a cause of acute mountain
sickness and that DLCO is an objective parameter to predict
adaptability to high altitude and the occurrence of HAPE.
5.1.5. Urine Volume after a Water Load. Huang et al. [22]
measured urine volume within 2.5h after participants
administered 1000mL of water at sea level in an eﬀort to
predict HAPE. They found that urine volume in subjects
who developed acute mountain response was signiﬁcantly
lower than that in the control group. In addition, the urine
v o l u m e sa t1 ,1 . 5 ,2 ,a n d2 . 5ha f t e rh y d r a t i o na n dt h et o t a l
urine volume within 1.5, 2, and2.5h after hydration were
negatively associated with AMS. They concludedthat greater
urine volume within 2.5h after hydration at sea level was
associated with mildersymptoms ofacutemountain sickness
after ascending to high altitude. Therefore, urine volume
after hydration might be a marker for acute mountain
sickness.
5.1.6. Blood Pressure and Blood pH. Zhou et al. [23]m e a -
sured the pH of blood in individuals before they ascended
to high altitude, in addition to PaCO2,a n dP a O 2.I n
that study, the blood pH was signiﬁcantly associated with
susceptibility to HAPE, and there was a signiﬁcant diﬀerence
in blood pH value between subjects who developed HAPE
and without HAPE. They found that during intense physical
labor following a rapid ascent to 4000m, the likelihood of
developing acute mountain sickness was signiﬁcantly greater
among individuals with blood pH > 7.45 than among those
with blood pH < 7.45. However, they found no signiﬁcant
diﬀerences in PaCO2 or PaO2 between these two groups of
subjects.Thus,theyconcludedthatbloodpH,butnotPaCO2
or PaO2, could be used as a predictor of HAPE.
5.1.7. Ventilatory Function. Zhou et al. [24]i n v e s t i g a t e d
the ventilatory functions in 113 newly recruited soldiers at
sea level, and then the soldiers were transferred to 3658m
by airplane. Two and three days after ascending to high
altitude, the investigators scored the symptoms of acute
mountain sickness and evaluated the relationship between
ventilatory functions and symptom scores. They found that
FVC, peak expiratory ﬂow, and forced expiratory volume
in 1 second in soldiers with HAPE were signiﬁcantly lower
than those in soldiers without HAPE. Thus, they speculated
that ventilatory functions at sea level could be used to screen
subjects susceptible to HAPE.6 Pulmonary Medicine
5.1.8.Cardiopulmonary Exercise Test. Wu and Li [25]in v es ti-
gated whether a cardiopulmonary exercise test could be used
to predict HAPE.They found that subjects with poor cardiac
and ventilatory responses to hypoxia were more susceptible
to HAPE. They assessed several parameters, including the
heart rate to oxygen saturation ratio (ΔHR/ΔSaO2)a n dt h e
minute ventilation to oxygen saturation ratio (ΔVE/ΔSaO2),
to establish a mathematical model that could predict HAPE.
They established a discriminant model based on Z = b1X1 +
b2X2, in which coeﬃcients b1 = 0.00769, b2 = 0.0810, and
Z0 = 0.472(discrimination threshold). Inthis model, Z>Z 0
is deﬁned as non-AMS and Z<Z 0 is deﬁned as AMS. The
discriminant modelhadahighsensitivity(93.9%)andahigh
accuracy (92.2%) for the prediction of HAPE.
5.2. Endocrine Parameters. Endocrine parameters may also
be used to predict HAPE. For example, Cai and Yang [26]
used radioimmunoassays to measure the blood levels of
18 endocrine parameters, including thyroid stimulating
hormone, adrenocorticotropic hormone, and corticotropin
hormone,and found thatplasma cortisol <20µg/Land urine
17-hydroxy corticosteroid (17-OHCS) levels <17µmoL/dL
could predict HAPE with an accuracy >95%.
5.3. Molecular Biological Parameters. Luo et al. [27–29]
compared the sequences of the mitochondrial genome in
HAPE patients and rats at high altitude versus sequences
from healthy individuals at high altitude and animals at
sea level, and identiﬁed single-nucleotide polymorphisms
in nine genes in mitochondrial DNA (T6680C, C3970T,
G3010A, A13497G, c15508T, G4164G, G1598A, C16111T,
and T7684C).Alloftheaﬀected genesencodedproteins con-
trolling mitochondrial electron transport. Based on single-
nucleotide polymorphism of mitochondrial DNA T6680C,
DNA C3970T, and DNA G3010A, they developed a kit that
can be used to predict susceptibility to HAPE. This kit can
be used to screen subjects for susceptibility to HAPE before
ascending to high altitude.
In another study, Qiu et al. [30] compared genetic
parameters of patients with HAPE, as well as people living in
Tibetan and Han Chinese migrants. They found that human
leucocyte antigen (HLA) DR6, particularly DR6(1402), was
associated with increased susceptibility to HAPE. Thus, they
speculatedthatsusceptibilitytoHAPEwasnotonlyrelatedto
genetic factors butwas also inﬂuenced by some susceptibility
genes.
6.EarlyPreventionof HAPE
Prevention of HAPE, as well as its associated symptoms
and signs, is important to reduce its incidence among
those ascending to high altitude. To achieve this, the
following factors are particularly important. (1) Maintain
body warmth with appropriate insulation and avoid upper
respiratory tract infection. Several days before ascending to
high altitude, bathing should be avoided to reduce exposure
to cold temperatures. (2) Avoid fatigue. Physical activity at
high altitude should be performed at an intensity of no more
than 60–80% of that at sea level and duration of activity
should be <6h. Similarly, the body must be given suﬃcient
time to rest both before and during the time at high altitude.
(3) Stopalcohol intake.Fifteen days before ascending to high
altitude, the consumption of alcohol should be stopped. (4)
Emotional stress. Unwanted emotional tension should be
avoided,while optimism and aggressiveness should be main-
tained. (5) Patients with upper respiratory tract infection
should be carefully monitored before and during the time at
highaltitude.However,delayingtheascentuntiltheinfection
has been fully resolved is preferable. (6) Oxygen must be
available at high altitude, either by maintaining high oxygen
levels in living quarters or by supplying compressed oxygen
tanks for use during physical activity. (7) Food and water
sanitation. Diets containing high levels of carbohydrates and
protein and low levels of fat are recommended. The intake of
vitamins can also be increased. (9) The use of drugs such as
Rhodiola rosea, Zangtianlu, Codonopsis compound tablets,
Shenqi pollen tablets, and acetazolamide during the time at
high altitude can also reduce the risk of HAPE.
Forpeopleworking at high altitude,such as construction
workers, preventative measures are particularly important.
As outlined above, it is essential to provide suﬃcient
nutrients, rest, and insulation against the cold, as well as to
limit labor intensity and duration of labor to avoid fatigue.
Shift-work is also recommended and may entail 20–30 days
of work at high altitude followed by a period of rest at
low altitude to provide more eﬀective resting conditions.
Shift-work also reduces the incidence of chronic mountain
sickness induced by long periods of physically demanding
work at high altitude. It is also essential to ensure there is
an adequate medical team to enable early detection, diag-
nosis, and treatment, should mountain sickness of HAPE
occur.
Finally, individuals planning on ascending to high alti-
tude should receive education regarding the prevention and
treatment of HAPE and take appropriate measures [31]t o
decrease the risk of developing HAPE: maintain a positive
attitude after ascending to high altitude take measures to
prevent HAPE, and consider the possible treatments be
optimistic but do not fear high altitude maintain body
temperature avoid hyperphagia stop smoking and alcohol
consumptionconductappropriateexcisebutavoidstrenuous
exercise and fatigue do not worry about trouble sleeping but
try to maintain good sleep quality pay attention to cough,
particularly cough event of bloody sputum and consider
seeking treatment consider bed rest and oxygen inhalation
be aware that headache, vomiting, and unsteady walking are
symptoms of HAPE and should be checked by a physician;
treatment should be started as soon as possible, even if the
symptoms are mild, as timely and comprehensive treatment
favors positive outcomes.
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